TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27686473

Group type: EXPERIMENTAL
Intervention: Positive Autobiographical Memories (AMs) shared first as general (AK) then specific (EAM)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Negative Autobiographical Memories (AMs) shared first as general (AK) then specific (EAM)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Order of sharing (AK first or EAM first)
Number of subjects: 148
Study: 26284720

Group type: EXPERIMENTAL
Intervention: Liraglutide (3.0 mg)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study: 24858158

Group type: EXPERIMENTAL
Intervention: Transrectal lidocaine gel (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intraprostatic lidocaine injection with intra rectal gel (Group II)
Number of subjects: 60
Study: 22037225

Group type: EXPERIMENTAL
Intervention: Airtraq™ laryngoscope
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GlideScope™
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LMA Fastrach™
Number of subjects: 30
Study: 19848198

Group type: EXPERIMENTAL
Intervention: Danhong Injection (DHI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (conventional treatment only)
Number of subjects: 100
Study: 17854429

Group type: EXPERIMENTAL
Intervention: TLR9 gene polymorphisms
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (102 randomized controls)
Number of subjects: 200
Study: 15590856

Group type: EXPERIMENTAL
Intervention: Triamcinolone injection with nimesulide (200 mg for seven days)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Triamcinolone injection with placebo (for seven days)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nimesulide group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 160
Study: 11593959

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (group or individual)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral treatment
Number of subjects: 36
Study: 9141548

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) therapy (0.625 mg daily)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: CEE in combination with medroxyprogesterone acetate (2.5 mg daily)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: CEE in combination with medroxyprogesterone acetate (10 mg daily on days 1-12)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: CEE in combination with micronized progesterone (200 mg daily on days 1-12)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: CEE therapy
Number of subjects: 875
Study: 7956109

Group type: EXPERIMENTAL
Intervention: Case management in conjunction with psychosocial rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychosocial rehabilitation only
Number of subjects: 0
Study: 3113291

Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 4 mg butorphanol
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 2 mg butorphanol
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol
Number of subjects: 122
Study: 29553843

Group type: EXPERIMENTAL
Intervention: Quince sauce (QS) 10 mg after meals
Number of subjects: 137

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 137
Study: 27370396

Group type: EXPERIMENTAL
Intervention: Standard radiotherapy (RT)
Number of subjects: 0
Study: 24874200

Group type: EXPERIMENTAL
Intervention: Previous HF hospitalization
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: Time interval from previous HF hospitalization to randomization
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: HF with preserved ejection fraction and previous HF hospitalization in the 6 months before randomization
Number of subjects: 7599
Study: 23486511

Group type: EXPERIMENTAL
Intervention: Whey protein (20 g)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate
Number of subjects: 161
Study: 20678148

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18988300

Group type: EXPERIMENTAL
Intervention: Frontal Slow EEG phenotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slowed Alpha Peak Frequency EEG phenotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study: 16635635

Group type: EXPERIMENTAL
Intervention: Custom-made ankle-foot orthosis (AFO)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Rigid hindfoot orthosis (HFO-R)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Articulated hindfoot orthosis (HFO-A)
Number of subjects: 13
Study: 12796726

Group type: EXPERIMENTAL
Intervention: Hypothetical surgical randomized controlled trials (RCTs)
Number of subjects: 0
Study: 11077380

Group type: EXPERIMENTAL
Intervention: Bioactive glass combined with calcium sulfate as a graft material
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no graft or calcium sulfate)
Number of subjects: 16
Study: 9587554

Group type: EXPERIMENTAL
Intervention: Alteplase and heparin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 10
Study: 7943865

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combined bolus injection of subnarcotic doses of sodium hydroxybutyrate and sodium thiopental
Number of subjects: 49
Study: 3091055

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 10 mg three times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transdermal nitrate (TN) one 10 cm2 patch daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transdermal nitrate (TN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 20
Study: 30039328

Group type: EXPERIMENTAL
Intervention: Healthy Families intervention
Number of subjects: 245
Study: 30773357

Group type: EXPERIMENTAL
Intervention: Collum Femoris Preserving (CFP) group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Zweymüller group
Number of subjects: 140
Study: 28204189

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 1341
Study: 25555450

Group type: EXPERIMENTAL
Intervention: Single i.v. dose of MAPC (10 million cells/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Once weekly for up to 5 doses of MAPC (1 or 5 million cells/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MAPC infusions
Number of subjects: 36
Study: 23766098

Group type: EXPERIMENTAL
Intervention: Liquid OLE (76.6 mg oleuropein, 14.5 mg hydroxytyrosol)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Capsulated OLE (76.6 mg oleuropein, 14.5 mg hydroxytyrosol)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Males receiving OLE
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: OLE (both formulations)
Number of subjects: 9
Study: 21272325

Group type: EXPERIMENTAL
Intervention: Supervisor telephone contact (STC) during maternity leave
Number of subjects: 541

Group type: COMPARATOR
Intervention: Common practice (CP)
Number of subjects: 541
Study: 19561152

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg o.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16757720

Group type: EXPERIMENTAL
Intervention: WBRT + SRS
Number of subjects: 132

Group type: COMPARATOR
Intervention: SRS alone
Number of subjects: 132
Study: 15087635

Group type: EXPERIMENTAL
Intervention: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil with 6 ml/h background infusion
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil with 9 ml/h background infusion
Number of subjects: 133

Group type: COMPARATOR
Intervention: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil without background infusion
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil (all groups)
Number of subjects: 133
Study: 11834229

Group type: EXPERIMENTAL
Intervention: One tablet of 750 microg levonorgestrel at time -12 h and one tablet at time 0 (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One tablet of 750 microg levonorgestrel at time 0 (Group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One tablet of 750 microg levonorgestrel at time -24 h and one tablet at time 0 (Group C)
Number of subjects: 24
Study: 9926761

Group type: EXPERIMENTAL
Intervention: DBM+CS implant
Number of subjects: 26

Group type: COMPARATOR
Intervention: Gingival flap surgery (GFS)
Number of subjects: 26
Study: 8050452

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with 6 g of highly concentrated ethyl esters of EPA and DHA daily for 4 months.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Dietary supplementation with 6 g of corn oil daily for 4 months (Control).
Number of subjects: 41
Study: 3390111

Group type: EXPERIMENTAL
Intervention: Combination of thiethylperazine (10 mg) and cimetidine (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of thiethylperazine (10 mg), cimetidine (300 mg), and promethazine (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 0
Study: 8245236

Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% shampoo
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Selenium sulfide 2.5% shampoo
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo shampoo
Number of subjects: 246
Study: 330575

Group type: EXPERIMENTAL
Intervention: Single daily intramuscular injection of sisomicin (160 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Two daily injections of sisomicin (80 mg)
Number of subjects: 50
Study: 31955480

Group type: EXPERIMENTAL
Intervention: Combined online and face-to-face continuing medical education (CME) programme
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (32 doctors from three provinces)
Number of subjects: 58
Study: 31149924

Group type: EXPERIMENTAL
Intervention: Attractive applicants
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Neutral applicants
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Obese applicants
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Race/Ethnicity
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Preclinical class rank
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Clinical clerkship grades
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Alpha Omega Alpha membership
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: United States Medical Licensing Examination Step 1 scores
Number of subjects: 74
Study: 27965377

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control
Number of subjects: 264
Study: 25847934

Group type: EXPERIMENTAL
Intervention: Cixutumumab plus androgen deprivation (AD)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Androgen deprivation (AD) alone
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cixutumumab plus AD
Number of subjects: 210
Study: 23831322

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV)
Number of subjects: 0
Study: 21661410

Group type: EXPERIMENTAL
Intervention: N‐butyl‐2‐cyanoacrylate injection
Number of subjects: 43

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation
Number of subjects: 43
Study: 19751517

Group type: EXPERIMENTAL
Intervention: Group physiotherapy sessions
Number of subjects: 174

Group type: COMPARATOR
Intervention: Individual physiotherapy sessions
Number of subjects: 174
Study: 16650669

Group type: EXPERIMENTAL
Intervention: Subconjunctival sodium hyaluronate 2.3%
Number of subjects: 55

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 55
Study: 15611216

Group type: EXPERIMENTAL
Intervention: BACE intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 78
Study: 11740831

Group type: EXPERIMENTAL
Intervention: Extended cardiac evaluations
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Beta-Blocker therapy
Number of subjects: 153

Group type: COMPARATOR
Intervention: Invasive intervention for CAD
Number of subjects: 153
Study: 10426663

Group type: EXPERIMENTAL
Intervention: PALA (1250 mg/m2 daily x 5 every 4 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: SAM (streptozotocin 400 mg/m2 IV daily x 5, doxorubicin 45 mg/m2 IV on day 1 and 22, methyl CCNU 60 mg/m2 orally on days 1 and 22 every 6 weeks)
Number of subjects: 73
Study: 8017464

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 2689478

Group type: EXPERIMENTAL
Intervention: TRUE Test
Number of subjects: 167

Group type: COMPARATOR
Intervention: Finn Chamber
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: TRUE Test and Finn Chamber
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: History prediction
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Past or present relevance
Number of subjects: 167
Study: 31791939

Group type: EXPERIMENTAL
Intervention: Pain review service
Number of subjects: 34
Study: 31023751

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 89
Study: 28077151

Group type: EXPERIMENTAL
Intervention: Multi-strategic intervention to increase implementation of a state‐wide healthy canteen policy
Number of subjects: 70

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 70
Study: 25812255

Group type: EXPERIMENTAL
Intervention: Health promotion intervention for CVD prevention among persons with SMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interest in participation
Number of subjects: 0
Study: 23936377

Group type: EXPERIMENTAL
Intervention: Acute exposure to moderate altitude (2590 m)
Number of subjects: 51
Study: 22044858

Group type: EXPERIMENTAL
Intervention: Baseline BMI
Number of subjects: 461
Study: 18073312

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Energy balance group (control)
Number of subjects: 18
Study: 16939848

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (300 mg twice a day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chemotherapy without vitamin E supplementation (Control)
Number of subjects: 32
Study: 12930195

Group type: EXPERIMENTAL
Intervention: Resistance-training group (RT; n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (CG; n = 19)
Number of subjects: 39
Study: 11916175

Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg orally three times per day for 7 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Azithromycin (1 g orally as a single dose)
Number of subjects: 39
Study: 9611062

Group type: EXPERIMENTAL
Intervention: HPV-16 positive
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HPV-18 positive
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both HPV-16 and HPV-18 positive
Number of subjects: 28
Study: 8072200

Group type: EXPERIMENTAL
Intervention: UFT (400 mg Tegafur plus 896 mg uracil/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: FT (800 mg/day)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: UFT
Number of subjects: 56

Group type: COMPARATOR
Intervention: FT
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: UFT and FT
Number of subjects: 56
Study: 3178506

Group type: EXPERIMENTAL
Intervention: Fish oil (4.5 g n‐3 PUFA's)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (same oil, n‐6 PUFA's)
Number of subjects: 14
Study: 31929213

Group type: EXPERIMENTAL
Intervention: Transparent film (nasal protective film)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no transparent film)
Number of subjects: 46
Study: 30616614

Group type: EXPERIMENTAL
Intervention: Lesinurad 200 mg plus febuxostat
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg plus febuxostat
Number of subjects: 196

Group type: COMPARATOR
Intervention: Febuxostat 80 mg (Control)
Number of subjects: 196
Study: 29273063

Group type: EXPERIMENTAL
Intervention: Inhaled Nitrous Oxide (N2O) for 1 hour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (SSRI) after N2O administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (air) for 1 hour
Number of subjects: 0
Study: 27004412

Group type: EXPERIMENTAL
Intervention: Photoplethysmography
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional mean arterial pressure
Number of subjects: 160
Study: 25739248

Group type: EXPERIMENTAL
Intervention: Paperboard and pad fixation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Short leg plaster
Number of subjects: 59
Study: 23063399

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 73

Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 73
Study: 19462722

Group type: EXPERIMENTAL
Intervention: Intravenous meperidine 50 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine 2% 5 mL periprostatic infiltration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study: 17846258

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 15103312

Group type: EXPERIMENTAL
Intervention: losartan treatment
Number of subjects: 560

Group type: COMPARATOR
Intervention: atenolol treatment
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: older patients
Number of subjects: 560
Study: 12270853

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg followed by 75 mg daily)
Number of subjects: 12562
Study: 10331998

Group type: EXPERIMENTAL
Intervention: Congenital heart disease group awaiting surgery
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy comparison group
Number of subjects: 3
Study: 7887658

Group type: EXPERIMENTAL
Intervention: Color slides
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Digital images
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Nine specific skin conditions
Number of subjects: 180
Study: 2403998

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day for 5 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day for an additional 5 weeks
Number of subjects: 108
Study: 45702

Group type: EXPERIMENTAL
Intervention: HALFD method (hypertonic albuminated fluid demand regimen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypertonic fluid and Ringer's lactate resuscitation
Number of subjects: 0
Study: 31590702

Group type: EXPERIMENTAL
Intervention: Intravenous co-amoxiclav (1 g of amoxicillin/200 mg of clavulanic acid)
Number of subjects: 3427

Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 3427
Study: 28192003

Group type: EXPERIMENTAL
Intervention: WEBCARE (online, 12-weeks fixed, 6 lesson behavioral treatment based on problem solving therapy)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 289
Study: 25630516

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus casei Shirota)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 17
Study: 23412642

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 12054

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12054
Study: 21252084

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1% drops four times daily for 1 week
Number of subjects: 111

Group type: COMPARATOR
Intervention: Hypromellose 0.3% drops four times daily for 1 week
Number of subjects: 111
Study: 19585395

Group type: EXPERIMENTAL
Intervention: Paliperidone ER with paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine alone
Number of subjects: 0
Study: 17762658

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Valsartan 640 mg
Number of subjects: 391
Study: 15626317

Group type: EXPERIMENTAL
Intervention: Soft tissue punch technique with deproteinized bovine bone mineral integrated in a 10% collagen matrix and free gingival graft from the palate.
Number of subjects: 20
Study: 11488790

Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 76
Study: 9530612

Group type: EXPERIMENTAL
Intervention: DR‐70 immunoassay kit
Number of subjects: 413
Study: 9391542

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg intravenously before chemotherapy)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Ondansetron (8 mg intravenously before chemotherapy, then every 8 hours for a total of 3 doses, plus 8 mg oral maintenance every 12 hours for 5 days)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 97

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 97
Study: 1895978

Group type: EXPERIMENTAL
Intervention: High osmolality contrast
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Low osmolality contrast
Number of subjects: 884

Group type: COMPARATOR
Intervention: No contrast (plain scan)
Number of subjects: 884
Study: 7119949

Group type: EXPERIMENTAL
Intervention: 500 IU vitamin D/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1,000 IU vitamin D/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 IU vitamin D/day (control group for infants)
Number of subjects: 0